Translating traditional clinical knowledge
into modern precision therapeutics

Two platforms. One translational thesis. Building on centuries of clinical observation to create the next generation of evidence-based treatments.

Medical Device

SilenEar™

Adaptive Neuromodulation

Closed-loop tinnitus therapy informed by acupuncture neuroscience. Personalized sound therapy combined with gentle nerve stimulation, guided by real-time physiological feedback.

FDA Pre-Sub Complete Hardware Alpha Clinical PI Confirmed 3 US Provisional Patents
Visit silenear.com
Drug Discovery

NaCo·AI

Computational Drug Discovery

AI-driven platform transforming clinically validated natural compounds into novel therapeutics for orphan and underserved diseases.

195K+ NCEs Generated 7 Provisional Patents Lead in Binding Assay Orphan + Animal Health
Explore NaCo·AI
One Thesis
Two Modalities

Both platforms share a common foundation: the systematic translation of insights from traditional clinical practice into validated modern therapeutics. SilenEar modernizes acupuncture-derived neuromodulation. NaCo·AI engineers drug candidates from the world's oldest clinical pharmacopoeia. Different modalities — same translational discipline.

Founder
Samuel Huang
Founder & CEO
NTU Chemistry · Xiamen University College of Medicine, TCM · NCCU Science & Technology Management · Grenoble DBA · Published in IEEE Bioinformatics
Contact

Business & Partnerships

bd@medisense.co

General Inquiries

info@medisense.co

Location

MediSense Inc.
Taichung, Taiwan